vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. kolmen lääkkeen yhdistelmähoito) lisänä ruokavalion ja liikunnan ohella potilaille riittävästi hallinnassa heidän maksimaalinen siedetty annos metformiinia ja sulfonyyliureaa. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
dutasteride/tamsulosinhydrochlorid ratiopharm 0,5 mg / 0,4 mg kapseli, kova
teva b.v. - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi
dutasteride/tamsulosinhydrochlorid stada 0,5 mg / 0,4 mg kapseli, kova
stada arzneimittel ag - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi
dutasteride/tamsulosinhydrochlorid medical valley 0,5 mg / 0,4 mg kapseli, kova
medical valley invest ab - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi
dutasteride/tamsulosinhydrochlorid glenmark 0,5 mg / 0,4 mg kapseli, kova
glenmark arzneimittel gmbh - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi
dutasteride/tamsulosinhydrochlorid accord 0,5 mg / 0,4 mg kapseli, kova
accord healthcare b.v. - dutasteride, tamsulosin hydrochloride - kapseli, kova - 0,5 mg / 0,4 mg - tamsulosiini ja dutasteridi
solomet depot c. bupivacain. hydrochlorid. 40 mg/ml + 5 mg/ml injektioneste, suspensio
orion corporation - bupivacaine hydrochloride monohydrate, methylprednisolone acetate - injektioneste, suspensio - 40 mg/ml + 5 mg/ml - metyyliprednisoloni
minims oxybuprocaine hydrochloride 4 mg/ml silmätipat, liuos, kerta-annospakkaus
bausch + lomb ireland limited - oxybuprocaine hydrochloride - silmätipat, liuos, kerta-annospakkaus - 4 mg/ml - oksibuprokaiini